Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05327465 · ClinicalTrials.gov registry record · NA

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

A NA study of Prostate Cancer and Prostate Cancer Metastatic, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
62
Enrollment target
1
Study location

NCT05327465: Recruiting NA study of Prostate Cancer and Prostate Cancer Metastatic, sponsored by Dana-Farber Cancer Institute.

NCT05327465 is a NA study of Prostate Cancer and Prostate Cancer Metastatic that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 62 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05327465, a NA study of Prostate Cancer and Prostate Cancer Metastatic, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
62 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer and are undergoing androgen deprivation therapy (ADT), and whether it will also improve physical fitness and function, body composition, and outcomes such as quality of life, cancer symptoms, and self-esteem. Participants in this study will be randomly assigned to one of two groups: 1) Aerobic and resistance exercise, or 2) Usual care.

Primary Outcome

Framingham Risk Score, an established comprehensive tool for evaluating the risk of developing cardiovascular disease using blood samples (i.e., low-density lipoprotein-cholesterol \[LDL-C\] or total cholesterol \[TC\], high-density lipoprotein-cholesterol \[HDL-C\]), demographic and medical profiles , and lifestyle behaviors (i.e., age, blood pressure, and diabetic and smoking status). The score ranges from -4 to 36 and the 10-year cardiovascular risk will be calculated accordingly (a higher sc

Interventions

  • OTHER Usual Care
  • OTHER Aerobic and resistance exercise

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 62 participants
Start Date 2022-08-11
Est. Completion 2026-12-31
Phase NA
Dana-Farber Cancer Institute

781 total trials

What NCT05327465 shows while recruiting

NCT05327465 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (90% lower).

The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.

NCT05327465 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05327465 about?

NCT05327465 is a clinical study titled "Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy". The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer and are undergoing androgen deprivation therapy (ADT), and whether it wi...

What is the current status of trial NCT05327465?

This trial is currently recruiting. It is a NA study. The enrollment target is 62 participants. The study started on 2022-08-11. Estimated completion is 2026-12-31.

What conditions does trial NCT05327465 study?

This clinical trial studies the following conditions: Prostate Cancer, Prostate Cancer Metastatic, Androgen Deprivation Therapy.

What interventions are being tested in trial NCT05327465?

The interventions under investigation include: Usual Care (OTHER), Aerobic and resistance exercise (OTHER).

Who is sponsoring clinical trial NCT05327465?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05327465 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05327465's enrollment target sits among peer trials

62 417th of 735 higher than 318 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03231150 · 62 participants · NA

    Plantar Fasciitis Randomized Clinical Control Trial

  • NCT03458676 · 62 participants · NA

    Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies

  • NCT03596086 · 62 participants · Phase 1

    HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

  • NCT03603405 · 62 participants · Phase 1

    HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05327465, the US trial registry maintained by the National Library of Medicine. NCT05327465 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.